IP Library Granted Patent US 8,003,325
Granted Patent B2
US 8,003,325 · App. 12/323,861 · Granted Aug 23, 2011

Polymorphisms of the BLyS gene and use in diagnostic methods

Assignee: Mayo Foundation for Medical Education and Research
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,003,325
App. No.
12/323,861
Granted
Aug 23, 2011
Kind
B2
Abstract

The present invention provides an isolated polynucleotide comprising at least one polymorphic nucleotide sequence, for example, the major alleles of the SNPs described as rs12583006, rs1224141, and rs1248930 and diagnostic assays for detecting the presence of these polymorphism associated with a condition associated with BLyS activity, such as hematological malignancy including B cell malignancies. The diagnostic assays are useful in predicting an individual's likelihood of developing a condition associated with BLyS activity, such as hematological malignancies, and for methods for treating an individual clinically diagnosed with a condition associated with BLyS activity, such as prediction of a patient's likelihood to respond to a specific drug treatment. The invention also provides an array of nucleic acid molecules immobilized on a solid surface, where at least one of the nucleic acid molecules comprises a BLyS polymorphic nucleic acid molecule. The nucleic acid arrays of the invention allow rapid detection of hybridizing nucleic acid-molecules, in a nucleic acid sample from an individual, of a BLyS polymorphism associated with hematological malignancy.

Claims (12)

1. A method of detecting a propensity of a human to develop a condition selected from the group consisting of B-cell non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma grade 1, follicular lymphoma grade 2, and follicular lymphoma grade 3, wherein said method comprises:

(a) detecting in a polynucleotide sample derived from said human the presence of a polymorphism in a B-lymphocyte stimulator (BLyS) gene, wherein said polymorphism is selected from the group consisting of a T allele at rs12583006, a T allele at rs122414, and an A allele at rs1248930, and

(b) classifying said human as having an increased propensity to develop said condition if said polymorphism is present.

2. The method of claim 1 , wherein said method comprises detecting in said polynucleotide sample the presence of two or more polymorphisms selected from said group, and classifying said human as having an increased propensity to develop said condition if said two or more polymorphisms are present.

3. The method of claim 2 , wherein said method comprises detecting in said polynucleotide sample the presence of three polymorphisms selected from said group and classifying said human as having an increased propensity to develop said condition if said three polymorphisms are present.

4. The method of claim 1 , wherein the presence of said polymorphism is determined by contacting a polynucleotide from said human with a polynucleotide probe which is capable of hybridizing to said polymorphism under stringent conditions; and determining whether hybridization has occurred, thereby indicating the presence of said polymorphism.

5. A method for identifying a human having an increased risk of developing a condition selected from the group consisting of B-cell non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma grade 1, follicular lymphoma grade 2, and follicular lymphoma grade 3, wherein said method comprises:

(a) detecting the presence of a polymorphism selected from the group consisting of a T allele at rs12583006, a T allele at rs122414, and an A allele at rs1248930 in a polynucleotide sample from said human, and

(b) classifying said human as having increased risk of developing said condition based on the presence of said polymorphism.

6. The method of claim 4 , wherein said method comprises detecting the presence of two or more polymorphisms selected from said group in said polynucleotide sample, and classifying said human as having increased risk of developing said condition when said two or more polymorphisms are present.

7. The method of claim 6 , wherein said method comprises detecting the presence of three polymorphisms selected from said group in said polynucleotide sample, and classifying said human as having increased risk of developing said condition when said three polymorphisms are present.

8. The method of claim 4 , wherein the presence of said polymorphism is detected by contacting said polynucleotide sample with a polynucleotide probe which is capable of hybridizing to said polymorphism under stringent conditions; and determining that hybridization has occurred, thereby indicating the presence of said polymorphism.

Assignments (3)
CONFIRMATORY LICENSE Recorded Feb 23, 2015
From: MAYO CLINIC ROCHESTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035061/0777 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2009
From: ANSELL, STEPHEN M.; NOVAK, ANNE J.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 023492/0345 →
CONFIRMATORY LICENSE Recorded Aug 21, 2009
From: MAYO FOUNDATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 023127/0682 →
Continuity (2)
Provisional Application 60991509 · Nov 30, 2007
Related Publication 20090253135A1 · Oct 8, 2009